Lurbinectedin is a chemotherapy drug that has been recently explored for its potential use in immunotherapy. However, the optimal dosage of lurbinectedin for immunotherapy is still under investigation.

According to the Drug Patent Watch [1], the recommended dosage of lurbinectedin for the treatment of relapsed small cell lung cancer is 3.2 mg/m2, administered intravenously over one hour every three weeks. However, this dosage may not be applicable for immunotherapy purposes.

A recent study published in the Journal of Clinical Oncology [2] evaluated the safety and efficacy of lurbinectedin in combination with pembrolizumab (an immunotherapy drug) in patients with advanced solid tumors. The study found that the combination therapy was well-tolerated and showed promising anti-tumor activity. However, the optimal dosage of lurbinectedin for this combination therapy was not specified in the study.

The FDA label for lurbinectedin [3] also does not provide information on the optimal dosage for immunotherapy. The label only specifies the recommended dosage for the treatment of relapsed small cell lung cancer.

In conclusion, the optimal dosage of lurbinectedin for immunotherapy is still under investigation and has not been established yet. Further studies are needed to determine the appropriate dosage for combination therapy with immunotherapy drugs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf